Carol Shields

Carol Shields is Chief of the Ocular Oncology Service at Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University in Philadelphia, USA

Content by Carol Shields:

Subspecialties Retina

Large Language Models: Is The Hype Real?

04/11/2024 | Antonio Yaghy, Carol Shields | 3 min read

Assessing the advantages and disadvantages of large language models

Subspecialties COVID-19

The Ocular Tumor Tsunami

09/16/2021 | Carol Shields

What more can be done to avoid devastating waves of advanced eye cancers?

Business & Profession Education and Training

Continuing Education

05/05/2021 | Carol Shields

Passing knowledge and good practices to new generations of ophthalmologists is vital for improving patient care

Business & Profession Professional Development

The Power of Stick-to-itness

03/29/2021 | Carol Shields

If women help each other on the way to the top, there are no limits to what they can achieve

Subspecialties COVID-19

Cancer Never Stops – and Neither Do We

09/21/2020 | Carol Shields

Organizing our ocular oncology service in unprecedented circumstances

Subspecialties Retina

A Job for Life

09/19/2018 | Carol Shields

Sitting Down With… Carol Shields, Chief of the Ocular Oncology Service at Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University in Philadelphia, USA

Business & Profession Other

The Uniqueness of Uveal Melanoma

05/16/2014 | Takami Sato , Carol Shields

Uveal and skin melanoma originate in the same type of cell, but are very different in terms of molecular mechanism, pathobiology, prognosis and therapeutic strategy. Here, the features of uveal melanoma are described and the latest therapeutic developments discussed.